A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.

Name: A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
Author: Taylor, Mike

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. — المؤلف: Taylor, Mike — Clinical ophthalmology (Auckland, N.Z.) 2019

المؤلف: Taylor, Mike
النشر: Clinical ophthalmology (Auckland, N.Z.) 2019
الوصف: 261-275 p.